PULM

Pulmatrix, Inc. [PULM] Stock Forecast

Q: What is Pulmatrix, Inc. stock symbol ?

Pulmatrix, Inc. is a US stock, located in Lexington of Ma and trading under the symbol PULM

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PULM Stock Summary

Earnings have grown 20.21% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

Does not have any significance market cap ($7.89M)

Profit margins (-2.35%) are lower than the previous year (-1.93%)

Top 10 Correlated ETFs

PULM

Top 10 Correlated Stocks

PULM

In the News

PULM Financial details

Company Rating

Neutral

Market Cap

7.89M

Income

-13.98M

Revenue

7.3M

Book val./share

4.93

Cash/share

5.25

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

10 May 2024

P/E

-0.47

Forward P/E

PEG

0.16

P/S

1.1

P/B

0.37

P/C

0.38

P/FCF

-0.38

Quick Ratio

5.01

Current Ratio

5.24

Debt / Equity

0.49

LT Debt / Equity

0.46

EPS (TTM)

-3.82

EPS next Y

EPS next Q

EPS this Y

-28.73%

EPS next Y

EPS next 5Y

EPS last 5Y

-30.79%

Revenue last 5Y

-1.6%

Revenue Q/Q

25.61%

EPS Q/Q

-44.66%

SMA20

SMA50

SMA100

Inst Own

2.9%

Inst Trans

0.25%

ROA

-44%

ROE

-63%

ROC

-0.52%

Gross Margin

100%

Oper. Margin

-248%

Profit Margin

-235%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.55-3.14

52W High

-33.33%

52W Low

+100%

RSI

Rel Volume

1.45

Avg Volume

15.73K

Volume

22.86K

Perf Week

5.26%

Perf Month

1.01%

Perf Quarter

6.96%

Perf Half Y

-0.5%

Beta

0.952

Volatility

0.04%, 0.17%

Prev Close

-4.31%

Price

Change

-3.85%

PULM Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	9.45	8.79	1.91	1.76	2
Net income per share	-24.37	-19.83	-8.31	-5.43	-3.87
Operating cash flow per share	3.86	-8.68	-7.28	-5.61	-4.38
Free cash flow per share	3.79	-8.88	-7.34	-5.64	-4.56
Cash per share	28.01	22.02	19.88	10.33	5.25
Book value per share	13.17	16.09	17.52	9.02	4.93
Tangible book value per share	4.62	11.12	17.52	9.02	4.93
Share holders equity per share	13.17	16.09	17.52	9.02	4.93
Interest debt per share	0.81	1.21	0.84	0.22	2.4
Market cap	14.39M	34.22M	23.73M	13.38M	6.79M
Enterprise value	-8.37M	4.3M	-27.83M	-21.39M	-3.62M
P/E ratio	-0.71	-1.2	-1.05	-0.71	-0.48
Price to sales ratio	1.82	2.71	4.59	2.2	0.93
POCF ratio	4.46	-2.74	-1.2	-0.69	-0.42
PFCF ratio	4.54	-2.68	-1.19	-0.69	-0.41
P/B Ratio	1.31	1.48	0.5	0.43	0.38
PTB ratio	1.31	1.48	0.5	0.43	0.38
EV to sales	-1.06	0.34	-5.38	-3.52	-0.5
Enterprise value over EBITDA	0.67	9.15	2.14	1.13	0.27
EV to operating cash flow	-2.59	-0.34	1.41	1.11	0.23
EV to free cash flow	-2.64	-0.34	1.4	1.1	0.22
Earnings yield	-1.42	-0.83	-0.95	-1.4	-2.08
Free cash flow yield	0.22	-0.37	-0.84	-1.45	-2.45
Debt to equity	0.06	0.08	0.05	0.03	0.49
Debt to assets	0.02	0.05	0.04	0.02	0.26
Net debt to EBITDA	1.81	-63.65	3.96	1.84	0.79
Current ratio	1.83	3.94	12.33	7.6	5.33
Interest coverage	0	0	0	170.69	0
Income quality	-0.16	0.65	0.98	1.03	1.13
Dividend Yield	0	0	0.13	0	0
Payout ratio	0	0	-0.14	0	0
Sales general and administrative to revenue	1.07	0.55	1.23	1.12	0.89
Research and developement to revenue	1.62	1.24	2.98	3	2.11
Intangibles to total assets	0.1	0.09	0	0	0
Capex to operating cash flow	-0.02	0.02	0.01	0	0.04
Capex to revenue	-0.01	-0.02	-0.03	-0.01	-0.09
Capex to depreciation	-0.08	-0.27	-0.12	-0.06	-0.46
Stock based compensation to revenue	0.26	0.09	0.22	0.18	0.13
Graham number	84.98	84.75	57.23	33.21	20.71
ROIC	-1.66	-0.03	-0.43	-0.57	-0.42
Return on tangible assets	-0.63	-0.82	-0.38	-0.46	-0.42
Graham Net	4.83	11.84	15.7	7.78	1.07
Working capital	14.22M	24.28M	50.34M	33.13M	16.93M
Tangible asset value	7.44M	19.56M	47.45M	31.11M	18M
Net current asset value	6.34M	17.51M	43.41M	28.3M	4.88M
Invested capital	0.06	0.08	0.05	0.03	0.49
Average receivables	3.6M	3.64M	75.5K	682.5K	1.11M
Average payables	891.5K	762.5K	882K	1.01M	1.55M
Average inventory	278K	611.5K	333.5K	76.5K	76.5K
Days sales outstanding	332.24	2.43	4.73	78.04	46.41
Days payables outstanding	17.05	0	19.91	280.66	473.88
Days of inventory on hand	15.8	0	0	36.15	0
Receivables turnover	1.1	150.4	77.15	4.68	7.86
Payables turnover	21.41	0	18.33	1.3	0.77
Inventory turnover	23.1	0	15.38M	10.1	0
ROE	-1.85	-1.23	-0.47	-0.6	-0.78
Capex per share	-0.07	-0.2	-0.05	-0.02	-0.19

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.47	0.41	0.5	0.48	0.6
Net income per share	-1.13	-1.18	-1.04	-1.03	-0.57
Operating cash flow per share	-1.39	-1.35	-1.34	-1.13	-0.55
Free cash flow per share	-1.39	-1.35	-1.36	-1.22	-0.63
Cash per share	9.79	8.42	7.06	5.84	5.25
Book value per share	8.55	7.4	6.42	5.44	4.93
Tangible book value per share	8.55	7.4	6.42	5.44	4.93
Share holders equity per share	8.55	7.4	6.42	5.44	4.93
Interest debt per share	0.21	0.18	0.1	2.36	2.4
Market cap	14.12M	10.66M	9.79M	7.41M	6.79M
Enterprise value	-20.65M	-19.31M	-15.64M	-5.3M	-3.62M
P/E ratio	-0.86	-0.62	-0.64	-0.49	-0.82
Price to sales ratio	8.27	7.11	5.31	4.23	3.09
POCF ratio	-2.8	-2.16	-2	-1.79	-3.38
PFCF ratio	-2.79	-2.16	-1.97	-1.66	-2.93
P/B Ratio	0.45	0.39	0.42	0.37	0.38
PTB ratio	0.45	0.39	0.42	0.37	0.38
EV to sales	-12.09	-12.88	-8.48	-3.02	-1.65
Enterprise value over EBITDA	5.25	4.62	4.41	1.35	1.8
EV to operating cash flow	4.09	3.92	3.19	1.28	1.8
EV to free cash flow	4.09	3.92	3.15	1.19	1.56
Earnings yield	-0.29	-0.4	-0.39	-0.51	-0.31
Free cash flow yield	-0.36	-0.46	-0.51	-0.6	-0.34
Debt to equity	0.03	0.03	0.02	0.43	0.49
Debt to assets	0.02	0.02	0.01	0.23	0.26
Net debt to EBITDA	8.83	7.16	7.16	3.23	5.16
Current ratio	7.6	6.93	7.61	5.24	5.33
Interest coverage	39.68	33.47	0	0	0
Income quality	1.2	1.11	1.29	1.1	0.97
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.92	1.47	0.91	0.99	0.41
Research and developement to revenue	2.62	2.58	2.26	2.26	1.58
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0.01	0.08	0.15
Capex to revenue	-0.01	0	-0.03	-0.18	-0.14
Capex to depreciation	-0.02	0	-0.13	-0.73	-1.47
Stock based compensation to revenue	0.16	0.2	0.14	0.12	0.09
Graham number	14.73	14.02	12.29	11.25	7.95
ROIC	-0.13	-0.16	-0.15	-0.09	-0.06
Return on tangible assets	-0.1	-0.12	-0.12	-0.1	-0.06
Graham Net	7.5	6.24	5.1	1.48	1.07
Working capital	33.13M	28.07M	23.78M	18.8M	16.93M
Tangible asset value	31.11M	27.01M	23.45M	19.88M	18M
Net current asset value	28.3M	23.75M	19.44M	6.34M	4.88M
Invested capital	0.03	0.03	0.02	0.43	0.49
Average receivables	887K	1.02M	579K	629.5K	884.5K
Average payables	1.17M	883K	753.5K	818K	1.31M
Average inventory	1.51M	1.03M	956.5K	773.5K	323.5K
Days sales outstanding	68.4	44.43	20.4	43.18	37.93
Days payables outstanding	274.86	129.73	190.02	149.37	828.61
Days of inventory on hand	244.09	227.36	184.09	136.69	0
Receivables turnover	1.32	2.03	4.41	2.08	2.37
Payables turnover	0.33	0.69	0.47	0.6	0.11
Inventory turnover	0.37	0.4	0.49	0.66	0
ROE	-0.13	-0.16	-0.16	-0.19	-0.12
Capex per share	0	0	-0.02	-0.09	-0.08

PULM Frequently Asked Questions

What is Pulmatrix, Inc. stock symbol ?

Pulmatrix, Inc. is a US stock , located in Lexington of Ma and trading under the symbol PULM

What is Pulmatrix, Inc. stock quote today ?

Pulmatrix, Inc. stock price is $2 today.

Is Pulmatrix, Inc. stock public?

Yes, Pulmatrix, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 15.73K
Market Capitalization 7.89M
Employee 22
CEO Mr. Teofilo David Raad MBA
Headquarters Lexington,MA,US
IPO Date 2014-03-21
Website https://www.pulmatrix.com

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.